Please provide your email address to receive an email when new articles are posted on . At 4 weeks, itching intensity scores decreased from 6.7 to 2.6 in the cannabis cream group. By comparison, ...
Every dermatologist encounters maddeningly pruritic patients at their wit's end. Our deficient understanding of and treating dermatology's essential symptom is even more exasperating. The following is ...
Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was ...
HSK21542, a selective agonist of kappa opioid receptors, significantly reduced itch intensity and quality of life over 12 weeks in patients receiving hemodialysis. HSK21542, a peripherally restricted ...
Company funded into early 2025 and expects bridging PK data in the US and Phase 2a results for chronic pruritus in primary biliary cholangitis (PBC) in 2024 BRIDGEWATER, NJ / ACCESSWIRE / December 11, ...
Higher disease acceptance in patients with psoriasis is linked to better outcomes, underscoring the need for psychological resilience in treatment. The study found illness acceptance negatively ...
Please provide your email address to receive an email when new articles are posted on . Increased joint pain and itch was significantly linked to an increase in overall fatigue. Disease severity was ...
The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback